{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:29:42Z","timestamp":1791174582817,"version":"4.1.0"},"reference-count":31,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with T-cell acute lymphoblastic leukemias (T-ALLs) within the Leuce\u0301mies Aigue\u0308s Lymphoblastiques de l'Adulte-94 (LALA-94) prospective trial were treated with a 4-drug per 4-week induction, with intermediate-dose cytarabine and mitoxantrone salvage treatment for patients not achieving complete remission (CR) in 1 course. Only the latter received allografts, if possible, thus providing an informative setting for assessing early response. Representative patients with T-ALL (91 patients) were classified into surface T-cell receptor (TCR)\u2013expressing T-ALL patients (TCR\u03b1\u03b2+ or TCR\u03b3\u03b4+), pre-\u03b1\u03b2 T-ALL patients (cTCR\u03b2+, TCR\u2013), and immature (IM) cTCR\u03b2\u2013, TCR\u2013 T-ALL patients; 81 patients underwent genotyping for SIL-TAL1, CALM-AF10, HOX11, and HOX11L2. Overall, CR was obtained in 81 (89%) patients; relapse rate was 62% at 4 years and overall survival (OS) rate was 38%. CR rate was significantly lower in IM T-ALL patients after 1 course (45% vs 87%; P &amp;lt; .001) and after salvage (74% vs 97%; P = .002), with the latter inducing a higher rate of CR (9 [64%] of 14) than initial induction. Once CR was obtained, cumulative relapse rates were similar for IM, pre-\u03b1\u03b2, and TCR+ T-ALL patients (P = .51), but were higher in HOX11L2 (83%) and SIL-TAL1 (82%) T-ALL patients compared with other genetic subgroups (48%; P = .05). This was associated with an inferior OS for HOX11L2 T-ALLs (13% vs 47% in HOX11L2-T-ALLs; P = .009). The majority of patients with HOX11 T-ALL underwent allografting, predominantly in second CR, but were not associated with a superior OS. Both TCR and genotypic stratification can therefore contribute to risk-adapted management of adult T-ALLs.<\/jats:p>","DOI":"10.1182\/blood-2004-09-3666","type":"journal-article","created":{"date-parts":[[2005,1,7]],"date-time":"2005-01-07T03:38:42Z","timestamp":1105069122000},"page":"3072-3078","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":60,"title":["Impact of TCR status and genotype on outcome in adult T-cell acute lymphoblastic leukemia: a LALA-94 study"],"prefix":"10.1182","volume":"105","author":[{"given":"Vahid","family":"Asnafi","sequence":"first","affiliation":[{"name":"From the Department of Hematology, Necker-Enfants-Malades, Saint Louis, and Pitie-Salpetriere; Assistance Publique-Hopitaux de Paris (AP-HP), Hopital Edouard Herriot, Lyon; Hopital Purpan, Toulouse; Institut Paoli Calmettes, Marseille; Hopital du Haut Leveque, Bordeaux; Centre Hospitalier Universitaire, Caen; and INSERM EMIU210, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Buzyn","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, Necker-Enfants-Malades, Saint Louis, and Pitie-Salpetriere; Assistance Publique-Hopitaux de Paris (AP-HP), Hopital Edouard Herriot, Lyon; Hopital Purpan, Toulouse; Institut Paoli Calmettes, Marseille; Hopital du Haut Leveque, Bordeaux; Centre Hospitalier Universitaire, Caen; and INSERM EMIU210, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Thomas","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, Necker-Enfants-Malades, Saint Louis, and Pitie-Salpetriere; Assistance Publique-Hopitaux de Paris (AP-HP), Hopital Edouard Herriot, Lyon; Hopital Purpan, Toulouse; Institut Paoli Calmettes, Marseille; Hopital du Haut Leveque, Bordeaux; Centre Hospitalier Universitaire, Caen; and INSERM EMIU210, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francoise","family":"Huguet","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, Necker-Enfants-Malades, Saint Louis, and Pitie-Salpetriere; Assistance Publique-Hopitaux de Paris (AP-HP), Hopital Edouard Herriot, Lyon; Hopital Purpan, Toulouse; Institut Paoli Calmettes, Marseille; Hopital du Haut Leveque, Bordeaux; Centre Hospitalier Universitaire, Caen; and INSERM EMIU210, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Vey","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, Necker-Enfants-Malades, Saint Louis, and Pitie-Salpetriere; Assistance Publique-Hopitaux de Paris (AP-HP), Hopital Edouard Herriot, Lyon; Hopital Purpan, Toulouse; Institut Paoli Calmettes, Marseille; Hopital du Haut Leveque, Bordeaux; Centre Hospitalier Universitaire, Caen; and INSERM EMIU210, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Boiron","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, Necker-Enfants-Malades, Saint Louis, and Pitie-Salpetriere; Assistance Publique-Hopitaux de Paris (AP-HP), Hopital Edouard Herriot, Lyon; Hopital Purpan, Toulouse; Institut Paoli Calmettes, Marseille; Hopital du Haut Leveque, Bordeaux; Centre Hospitalier Universitaire, Caen; and INSERM EMIU210, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oumedaly","family":"Reman","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, Necker-Enfants-Malades, Saint Louis, and Pitie-Salpetriere; Assistance Publique-Hopitaux de Paris (AP-HP), Hopital Edouard Herriot, Lyon; Hopital Purpan, Toulouse; Institut Paoli Calmettes, Marseille; Hopital du Haut Leveque, Bordeaux; Centre Hospitalier Universitaire, Caen; and INSERM EMIU210, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Cayuela","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, Necker-Enfants-Malades, Saint Louis, and Pitie-Salpetriere; Assistance Publique-Hopitaux de Paris (AP-HP), Hopital Edouard Herriot, Lyon; Hopital Purpan, Toulouse; Institut Paoli Calmettes, Marseille; Hopital du Haut Leveque, Bordeaux; Centre Hospitalier Universitaire, Caen; and INSERM EMIU210, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Lheritier","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, Necker-Enfants-Malades, Saint Louis, and Pitie-Salpetriere; Assistance Publique-Hopitaux de Paris (AP-HP), Hopital Edouard Herriot, Lyon; Hopital Purpan, Toulouse; Institut Paoli Calmettes, Marseille; Hopital du Haut Leveque, Bordeaux; Centre Hospitalier Universitaire, Caen; and INSERM EMIU210, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"Vernant","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, Necker-Enfants-Malades, Saint Louis, and Pitie-Salpetriere; Assistance Publique-Hopitaux de Paris (AP-HP), Hopital Edouard Herriot, Lyon; Hopital Purpan, Toulouse; Institut Paoli Calmettes, Marseille; Hopital du Haut Leveque, Bordeaux; Centre Hospitalier Universitaire, Caen; and INSERM EMIU210, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Fiere","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, Necker-Enfants-Malades, Saint Louis, and Pitie-Salpetriere; Assistance Publique-Hopitaux de Paris (AP-HP), Hopital Edouard Herriot, Lyon; Hopital Purpan, Toulouse; Institut Paoli Calmettes, Marseille; Hopital du Haut Leveque, Bordeaux; Centre Hospitalier Universitaire, Caen; and INSERM EMIU210, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Macintyre","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, Necker-Enfants-Malades, Saint Louis, and Pitie-Salpetriere; Assistance Publique-Hopitaux de Paris (AP-HP), Hopital Edouard Herriot, Lyon; Hopital Purpan, Toulouse; Institut Paoli Calmettes, Marseille; Hopital du Haut Leveque, Bordeaux; Centre Hospitalier Universitaire, Caen; and INSERM EMIU210, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herve\u0301","family":"Dombret","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, Necker-Enfants-Malades, Saint Louis, and Pitie-Salpetriere; Assistance Publique-Hopitaux de Paris (AP-HP), Hopital Edouard Herriot, Lyon; Hopital Purpan, Toulouse; Institut Paoli Calmettes, Marseille; Hopital du Haut Leveque, Bordeaux; Centre Hospitalier Universitaire, Caen; and INSERM EMIU210, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021218472772800_REF1","doi-asserted-by":"crossref","unstructured":"Boucheix C, David B, Sebban C, et al. Immunophenotype of adult acute lymphoblastic leukemia, clinical parameters, and outcome: an analysis of a prospective trial including 562 tested patients (LALA87). French Group on Therapy for Adult Acute Lymphoblastic Leukemia. Blood. 1994;84:1603-1612.","DOI":"10.1182\/blood.V84.5.1603.bloodjournal8451603"},{"key":"2020021218472772800_REF2","doi-asserted-by":"crossref","unstructured":"Pui CH, Behm FG, Singh B, et al. Heterogeneity of presenting features and their relation to treatment outcome in 120 children with T-cell acute lymphoblastic leukemia. Blood. 1990;75:174-179.","DOI":"10.1182\/blood.V75.1.174.174"},{"key":"2020021218472772800_REF3","doi-asserted-by":"crossref","unstructured":"Ferrando AA, Neuberg DS, Staunton J, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 2002;1:75-87.","DOI":"10.1016\/S1535-6108(02)00018-1"},{"key":"2020021218472772800_REF4","doi-asserted-by":"crossref","unstructured":"Asnafi V, Beldjord K, Libura M, et al. Age-related phenotypic and oncogenic differences in T-acute lymphoblastic leukemias may reflect thymic atrophy. Blood. 2004;104:4173-4180.","DOI":"10.1182\/blood-2003-11-3944"},{"key":"2020021218472772800_REF5","doi-asserted-by":"crossref","unstructured":"Chiaretti S, Li X, Gentleman R, et al. Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival. Blood. 2004;103:2771-2778.","DOI":"10.1182\/blood-2003-09-3243"},{"key":"2020021218472772800_REF6","doi-asserted-by":"crossref","unstructured":"Kees UR, Heerema NA, Kumar R, et al. Expression of HOX11 in childhood T-lineage acute lymphoblastic leukaemia can occur in the absence of cytogenetic aberration at 10q24: a study from the Children's Cancer Group (CCG). Leukemia. 2003;17:887-893.","DOI":"10.1038\/sj.leu.2402892"},{"key":"2020021218472772800_","unstructured":"Kikuchi A, Hayashi Y, Kobayashi S, et al. Clinical significance of TAL1 gene alteration in childhood T-cell acute lymphoblastic leukemia and lymphoma. Leukemia. 1993;7:933-938."},{"key":"2020021218472772800_REF8","doi-asserted-by":"crossref","unstructured":"Ballerini P, Blaise A, Busson-Le Coniat M, et al. HOX11L2 expression defines a clinical subtype of pediatric T-ALL associated with poor prognosis. Blood. 2002;100:991-997.","DOI":"10.1182\/blood-2001-11-0093"},{"key":"2020021218472772800_REF9","doi-asserted-by":"crossref","unstructured":"Cave H, Suciu S, Preudhomme C, et al. Clinical significance of HOX11L2 expression linked to t(5; 14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951. Blood. 2004;103:442-450.","DOI":"10.1182\/blood-2003-05-1495"},{"key":"2020021218472772800_REF10","doi-asserted-by":"crossref","unstructured":"Ferrando AA, Neuberg DS, Dodge RK, et al. Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia. Lancet. 2004;363:535-536.","DOI":"10.1016\/S0140-6736(04)15542-6"},{"key":"2020021218472772800_REF11","doi-asserted-by":"crossref","unstructured":"Asnafi V, Beldjord K, Boulanger E, et al. Analysis of TCR, pT alpha, and RAG-1 in T-acute lymphoblastic leukemias improves understanding of early human T-lymphoid lineage commitment. Blood. 2003;101:2693-2703.","DOI":"10.1182\/blood-2002-08-2438"},{"key":"2020021218472772800_REF12","doi-asserted-by":"crossref","unstructured":"Asnafi V, Radford-Weiss I, Dastugue N, et al. CALM-AF10 is a common fusion transcript in T-ALL and is specific to the TCRgammadelta lineage. Blood. 2003;102:1000-1006.","DOI":"10.1182\/blood-2002-09-2913"},{"key":"2020021218472772800_REF13","doi-asserted-by":"crossref","unstructured":"Macintyre EA, Smit L, Ritz J, Kirsch IR, Strominger JL. Disruption of the SCL locus in T-lymphoid malignancies correlates with commitment to the T-cell receptor alpha beta lineage. Blood. 1992;80:1511-1520.","DOI":"10.1182\/blood.V80.6.1511.1511"},{"key":"2020021218472772800_REF14","doi-asserted-by":"crossref","unstructured":"Schneider NR, Carroll AJ, Shuster JJ, et al. New recurring cytogenetic abnormalities and association of blast cell karyotypes with prognosis in childhood T-cell acute lymphoblastic leukemia: a pediatric oncology group report of 343 cases. Blood. 2000;96:2543-2549.","DOI":"10.1182\/blood.V96.7.2543"},{"key":"2020021218472772800_REF15","doi-asserted-by":"crossref","unstructured":"Gray R. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1998;16:1141-1154.","DOI":"10.1214\/aos\/1176350951"},{"key":"2020021218472772800_REF16","doi-asserted-by":"crossref","unstructured":"Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.","DOI":"10.1080\/01621459.1958.10501452"},{"key":"2020021218472772800_REF17","doi-asserted-by":"crossref","unstructured":"Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc. 1972;135:185-206.","DOI":"10.2307\/2344317"},{"key":"2020021218472772800_REF18","doi-asserted-by":"crossref","unstructured":"Cox D. Regression models and life-tables. J R Stat Soc. 1972;134:187-220.","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"2020021218472772800_REF19","doi-asserted-by":"crossref","unstructured":"Thomas X, Boiron JM, Huguet F, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 2004;22(20): 4075-4086.","DOI":"10.1200\/JCO.2004.10.050"},{"key":"2020021218472772800_REF20","unstructured":"Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995;9:1783-1786."},{"key":"2020021218472772800_REF21","doi-asserted-by":"crossref","unstructured":"Mauvieux L, Leymarie V, Helias C, et al. High incidence of Hox11L2 expression in children with T-ALL. Leukemia. 2002;16:2417-2422.","DOI":"10.1038\/sj.leu.2402709"},{"key":"2020021218472772800_REF22","doi-asserted-by":"crossref","unstructured":"Delabesse E, Bernard M, Landman-Parker J, et al. Simultaneous SIL-TAL1 RT-PCR detection of all tal(d) deletions and identification of novel tal(d) variants. Br J Haematol. 1997;99:901-907.","DOI":"10.1046\/j.1365-2141.1997.4833286.x"},{"key":"2020021218472772800_REF23","doi-asserted-by":"crossref","unstructured":"Breit TM, Mol EJ, Wolvers-Tettero IL, Ludwig WD, van Wering ER, van Dongen JJ. Site-specific deletions involving the tal-1 and sil genes are restricted to cells of the T cell receptor alpha\/beta lineage: T cell receptor delta gene deletion mechanism affects multiple genes. J Exp Med. 1993;177:965-977.","DOI":"10.1084\/jem.177.4.965"},{"key":"2020021218472772800_REF24","doi-asserted-by":"crossref","unstructured":"Bash RO, Crist WM, Shuster JJ, et al. Clinical features and outcome of T-cell acute lymphoblastic leukemia in childhood with respect to alterations at the TAL1 locus: a Pediatric Oncology Group study. Blood. 1993;81:2110-2117.","DOI":"10.1182\/blood.V81.8.2110.2110"},{"key":"2020021218472772800_REF25","unstructured":"Stock W, Westbrook CA, Sher DA, et al. Low incidence of TAL1 gene rearrangements in adult acute lymphoblastic leukemia: a cancer and leukemia group B study (8762). Clin Cancer Res. 1995;1:459-463."},{"key":"2020021218472772800_REF26","unstructured":"Pui CH, Rivera GK, Hancock ML, et al. Clinical significance of CD10 expression in childhood acute lymphoblastic leukemia. Leukemia. 1993;7:35-40."},{"key":"2020021218472772800_","doi-asserted-by":"crossref","unstructured":"Pui CH, Hancock ML, Head DR, et al. Clinical significance of CD34 expression in childhood acute lymphoblastic leukemia. Blood. 1993;82:889-894.","DOI":"10.1182\/blood.V82.3.889.889"},{"key":"2020021218472772800_","doi-asserted-by":"crossref","unstructured":"Pullen J, Shuster JJ, Link M, et al. Significance of commonly used prognostic factors differs for children with T cell acute lymphocytic leukemia (ALL), as compared to those with B-precursor ALL: a Pediatric Oncology Group (POG) study. Leukemia. 1999;13:1696-1707.","DOI":"10.1038\/sj.leu.2401555"},{"key":"2020021218472772800_","doi-asserted-by":"crossref","unstructured":"Uckun FM, Steinherz PG, Sather H, et al. CD2 antigen expression on leukemic cells as a predictor of event-free survival after chemotherapy for T-lineage acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 1996;88:4288-4295.","DOI":"10.1182\/blood.V88.11.4288.bloodjournal88114288"},{"key":"2020021218472772800_","doi-asserted-by":"crossref","unstructured":"Niehues T, Kapaun P, Harms DO, et al. A classification based on T cell selection-related phenotypes identifies a subgroup of childhood T-ALL with favorable outcome in the COALL studies. Leukemia. 1999;13:614-617.","DOI":"10.1038\/sj.leu.2401382"},{"key":"2020021218472772800_REF31","unstructured":"Consolini R, Legitimo A, Rondelli R, et al. Clinical relevance of CD10 expression in childhood ALL. The Italian Association for Pediatric Hematology and Oncology (AIEOP). Haematologica. 1998;83:967-973."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/105\/8\/3072\/1709300\/zh800805003072.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/105\/8\/3072\/1709300\/zh800805003072.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,5]],"date-time":"2020-04-05T07:03:37Z","timestamp":1586070217000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/105\/8\/3072\/20578\/Impact-of-TCR-status-and-genotype-on-outcome-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4,15]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2005,4,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2004-09-3666","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,4,15]]}}}